Introduction:

Inotropic drugs are required in order to stabilise patients with acute heart failure.

Objective:

To determine which of the inotropic drugs are associated with lower mortality.

Materials and method:

A network meta-analysis was performed using the frequentist approach. The systematic search included PUBMED, EMBASE, CENTRAL, DARE, Epistemonikos, ScieELO, LILACS, and OpenGray data bases. Randomised clinical trials were included that provided data on mortality on patients with acute heart failure who received dobutamine, levosimendan or milrinone.

Results:

A total of 5,315 patients in the 20 studies include were randomly assigned to five comparisons. The majority of the studies showed bias risks in population selection and in the blinding of the intervention. The different comparisons with placebo, dobutamine (OR 1.30; 95% probability interval (PI); 0.54-3.09), levosimendan (OR 0.86; 95% PI; 0.38-1.93), and milrinone (OR 1.69; 95% PI; 0.49-5.85), did not show any statistically significant differences. The same applied to the comparisons between themselves, dobutamine vs. levosimendan (OR 0.66; 95%PI; 0.30-1.48), dobutamine vs. milrinone (OR 1.30; 95% PI; 0.34-4.96), and levosimendan vs. milrinone (OR 1.97; 95% PI; 0.53-7.29). The analysis by ranges showed a higher probability for milrinone, followed by dobutamine.

Discussion:

There are no differences in the use of inotropic drugs, such as dobutamine, levosimendan or milrinone in terms of mortality outcomes. Their use, therefore, will depend on other factors.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )